Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
NCT04697056 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
- Lead sponsor
- Vanda Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 25, 2021
- Completion date
- November 19, 2021
- Enrollment
- 5 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.